NO120371B - - Google Patents
Download PDFInfo
- Publication number
- NO120371B NO120371B NO165984A NO16598466A NO120371B NO 120371 B NO120371 B NO 120371B NO 165984 A NO165984 A NO 165984A NO 16598466 A NO16598466 A NO 16598466A NO 120371 B NO120371 B NO 120371B
- Authority
- NO
- Norway
- Prior art keywords
- demethyl
- epipodophyllotoxin
- glucoside
- chloroform
- carbobenzoxy
- Prior art date
Links
- 229930182478 glucoside Natural products 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 64
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 229960001237 podophyllotoxin Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000007859 condensation product Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229940057499 anhydrous zinc acetate Drugs 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical class CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- 208000007093 Leukemia L1210 Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Substances FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- FDJABJJEKWDNQO-UHFFFAOYSA-N pentane;propan-2-one Chemical compound CC(C)=O.CCCCC FDJABJJEKWDNQO-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- PDWQYOPXBHPSCA-UHFFFAOYSA-N 1,2-dichloroethane;oxolane Chemical compound ClCCCl.C1CCOC1 PDWQYOPXBHPSCA-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- -1 demethyl podophyllotoxin Chemical compound 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Fremgangsmåte for fremstilling av nye, terapeutiske aktive 4<1->demetyl-epipodofyllotoksin-glukosider. Process for the production of new, therapeutically active 4<1->demethyl-epipodophyllotoxin glucosides.
Foreliggende oppfinnelse angår en fremgangsmåte for fremstillingThe present invention relates to a method for production
av nye, terapeutisk aktive lf -demetyl-epipodofyllotoksin-glukosider med den alminnelige formel (!)■ of new, therapeutically active lf-demethyl-epipodophyllotoxin glucosides with the general formula (!)■
hvor R står for en fenyl-, 2-furyl- eller en 2-tienyl-rest, og det særegne ved fremgangsmåten i henhold til oppfinnelsen er at where R stands for a phenyl, 2-furyl or a 2-thienyl residue, and the distinctive feature of the method according to the invention is that
•+* -demetyl-epipodofyllotoksin-(3-D-glukosid med formel (II)•+* -Demethyl-epipodophyllotoxin-(3-D-glucoside of formula (II)
i nærvær av en sur katalysator omsettes med et aldehyd med den alminnelige formel (III) in the presence of an acidic catalyst is reacted with an aldehyde of the general formula (III)
hvor R har den ovenfor angitte betydning. Som katalysator kommer f.eks. Lewissyrer, som vannfritt sinkklorid, eller en torret kation-utbytter med sulfonsyregrupper i - formen på tale. where R has the meaning given above. As a catalyst comes e.g. Lewis acids, such as anhydrous zinc chloride, or a dry cation exchanger with sulfonic acid groups in - the form of speech.
Særlig fordelaktig er det å lose opp V-demetyl-epipodofyllotoksin-B-D-glukosid direkte i rent aldehyd og tilsette katalysatoren. Omsetningen forloper vanlig ved romtemperatur eller ved noe forhoyet temperatur og er i stor utstrekning avsluttet etter 1 til 10 timer, ved 20°C oftest etter 3-6 timer. It is particularly advantageous to dissolve V-demethyl-epipodophyllotoxin-B-D-glucoside directly in pure aldehyde and add the catalyst. The reaction usually proceeds at room temperature or at a somewhat elevated temperature and is largely completed after 1 to 10 hours, at 20°C most often after 3-6 hours.
For isolering av kondensasjonsproduktet behandles reaksjonsblandingen i et med vann ikke blandbart lbsningsmiddel, f.eks. kloroform, det utrystes flere ganger med vann for fjerning av vannlose-lige salter og biprodukter, den organiske fase tbrres og inndampes i vakuum, hvorved hovedmengden av det overskytende aldehyd fjernes. Det erholdes en oljeaktig rest, hvorfra de siste rester av aldehydet lett fjernes ved skylling av kondensasjonsproduktet med et egnet lbsningsmiddel, som f.eks. petroleter, pentan, heksan eller ved kromatografering på et nbytralt reagerende adsorbsjonsmiddel, som f.eks. silikagel. Kondensasjonsproduktet isoleres og renses på kjent måte, f.eks. ved kromatografering eller omkrystallisering. To isolate the condensation product, the reaction mixture is treated in a water-immiscible solvent, e.g. chloroform, it is shaken several times with water to remove water-soluble salts and by-products, the organic phase is filtered and evaporated in a vacuum, whereby the main amount of the excess aldehyde is removed. An oily residue is obtained, from which the last remnants of the aldehyde are easily removed by rinsing the condensation product with a suitable solvent, such as e.g. petroleum ether, pentane, hexane or by chromatography on a neutrally reacting adsorbent, such as e.g. silica gel. The condensation product is isolated and purified in a known manner, e.g. by chromatography or recrystallization.
hf - demetyl- epipodofyllotoksin- P- D- glukosid ( formel II)hf - demethyl- epipodophyllotoxin- P- D- glucoside (formula II)
Det for fremstilling av de nye forbindelser med den alminnelige formel I tjenende utgangsstoff h'-demetyl-epipodofyllotoksin-B-D-glukosid fremstilles etter en av de følgende fremgangsmåter: Enten avspalter man fra tetra-O-acetyl-M-1 -karbo-benzoksy-^-' -demetyl-epipodofyllotoksin-B-D-glukosid med formel (IV) The starting material h'-demethyl-epipodophyllotoxin-B-D-glucoside, which serves for the preparation of the new compounds with the general formula I, is prepared according to one of the following methods: Either one cleaves from tetra-O-acetyl-M-1 -carbo-benzoxy- ^-'-Demethyl-epipodophyllotoxin-B-D-glucoside of formula (IV)
forst karbobenzoksygruppen hydrogenolytisk, og det således erholdte tetra-O-acetyl-^'-dernetyl-epipdofyllotoksin-B-D-glukosid med formel(V) underkastes en alkoholyse i nærvær av vannfritt sinkacetat, eller man avspaltér forst acetylgruppene i tetra-O-acetyl-U-<1->karbobenzoksy-^1-dernety1-epipodofyllotoksin-B-D-glukosid alkoholytisk i nærvær av vannfritt sinkacetat eller en blanding av vannfritt sinkacetat/natriumacetat, idet samtidig delvis også karbobenzoksygruppen avspaltes. Fra den således dannede blanding av reaksjons-komponenter lar det tidligere ukjente V-karbobenzoksy-V-demetyl-epipodofyllotoksin-B-D-€Lukosid med formel (VI) first the carbobenzoxy group hydrogenolytically, and the thus obtained tetra-O-acetyl-^'-dernetyl-epidophyllotoxin-B-D-glucoside of formula (V) is subjected to an alcoholysis in the presence of anhydrous zinc acetate, or one first splits off the acetyl groups in tetra-O-acetyl- U-<1->carbobenzoxy-^1-dernety1-epipodophyllotoxin-B-D-glucoside alcoholytically in the presence of anhydrous zinc acetate or a mixture of anhydrous zinc acetate/sodium acetate, the carbobenzoxy group being partially split off at the same time. From the thus formed mixture of reaction components, the previously unknown V-carbobenzoxy-V-demethyl-epipodophyllotoxin-B-D-€Lucoside of formula (VI)
seg isolere, hvilket videre ved hydrogenolyse av karbobenzoksygruppen overfores i h1-demetyl-epipodofyllotoksin-B-D-glukosid. is isolated, which is further converted by hydrogenolysis of the carbobenzoxy group into h1-demethyl-epipodophyllotoxin-B-D-glucoside.
Tetra-O-acetyl-4-' -karbobenzoksy-U-' -demetyl-epipodofyllotoksin-3- D- glukosid ( formel IV) Tetra-O-acetyl-4-'-carbobenzoxy-U-'-demethyl-epipodophyllotoxin-3-D-glucoside (Formula IV)
Det for fremstilling av h'-demetyl-epipodofyllotoksin-8-D-glukosid tjenende utgangsstoff tetra-O-acetyl-^-i-karbobenzoksy-^1 -demetyl-epipodofyllotoksin-(3-D-glukosid kan fremstilles på folgende måte: The starting material used for the production of h'-demethyl-epipodophyllotoxin-8-D-glucoside, tetra-O-acetyl-^-i-carbobenzoxy-^1-demethyl-epipodophyllotoxin-(3-D-glucoside), can be prepared in the following way:
Det ble funnet at omsetning av 2,3,^,6-tetra-0-acetyl-(3-D-glukoseIt was found that turnover of 2,3,^,6-tetra-0-acetyl-(3-D-glucose
i form av dets rene 8-anomer såvel med h'-karbo benzoksy-1*-1-demetyl-podofyllotoksin med formel (VIII) in the form of its pure 8-anomer as well as with h'-carbo benzoxy-1*-1-demethyl podophyllotoxin of formula (VIII)
såvel som med h<1->karbobensoksy-H-'-demetyl-epipodofyllotoksin med formel (VII) as well as with h<1->carbobenzoxy-H-'-demethyl-epipodophyllotoxin of formula (VII)
dvs. uavhengig av stereokjemien for OH-gruppen på C-l karbonatomet i aglykonet, i nærvær av bortrifluorid-etyleterat ved en temperatur på under 0°C i et under reaksjonsbetingelsene inert løsningsmiddel forer til tetra-O-acetyl-^-' -karbobenzoksy-H-' -demetyl-epipodofyllotoksin-B-D-glukosid. i.e. regardless of the stereochemistry of the OH group on the C-1 carbon atom in the aglycone, in the presence of boron trifluoride ethyl etherate at a temperature below 0°C in a solvent inert under the reaction conditions leads to tetra-O-acetyl-^-'-carbobenzoxy-H -' -Demethyl-epipodophyllotoxin-B-D-glucoside.
'+' -karbobenzoksy-H-1 -demetyl-podofyllotoksin (formel VIII) og ij-' - karbobenzoksy-^- 1 - demetyl- epipodofyllotoksin ( formel VII) '+'-carbobenzoxy-H-1-demethyl-podophyllotoxin (formula VIII) and ij-'-carbobenzoxy-^-1-demethyl-epipodophyllotoxin (formula VII)
De for fremstilling av tetra-O-acetyl-V -karbobenzoksy-^' -demetyl-epipodofyllotoksin-B-D-glukosid tjenende utgangsstoffer V-karbobenzoksy-V'-demetylpodofyllotoksin henhv. h'-karbobenzoksy-^-1 - demetyl-epipodofyllotoksin fremstilles ved hjelp av den folgende fremgangsmåte: The starting materials used for the production of tetra-O-acetyl-V-carbobenzoxy-^'-demethyl-epipodophyllotoxin-B-D-glucoside V-carbobenzoxy-V'-demethylpodophyllotoxin resp. h'-carbobenzoxy-^-1-demethyl-epipodophyllotoxin is produced using the following method:
1-demetyl-podofyllotoksin med formel (IX)1-Demethyl-podophyllotoxin of formula (IX)
henholdsvis ^'-demetyl-epipodofyllotoksin med formel (X) respectively ^'-demethyl-epipodophyllotoxin of formula (X)
omsettes i et vannfritt og under reaksjonsbetingelsene inert organisk lbsningsmiddel ved temperaturer mellom «-20 og t- 5°C i nærvær av en tertiær organisk base med klormaursyrebenzylester til is reacted in an anhydrous and, under the reaction conditions, inert organic solvent at temperatures between -20 and t-5°C in the presence of a tertiary organic base with chloroformic acid benzyl ester to
>+'-karbobenzoksy-V'-demetyl-podofyllotoksin henholdsvis h'-karbobenzoksy-M-'-demetyl-epipodofyllotoksin. >+'-carbobenzoxy-V'-demethyl-podophyllotoxin or h'-carbobenzoxy-M-'-demethyl-epipodophyllotoxin.
Det som utgangsma terial anvendte *+' -demetyl-epipodofyllo-toksin kan erholdes ved epimerisering av<>>+'-dernetyl-podofyllo-toksin (se eksempel 1). Fremstillingen av h1 -karbobenzoksy-^f' -demetyl-podofyllotoksin skjer på samme måte, utgående fra V-demetyl-podofyllotoksin, idet det pr. mol V-demetyl-podofyllotoksin anvendes 1 - 1,6 mol karbobenzoksyklorid. The *+'-demethyl-epipodophyllo-toxin used as starting material can be obtained by epimerization of<>>+'-dernetyl-podophyllo-toxin (see example 1). The production of h1-carbobenzoxy-^f'-demethyl-podophyllotoxin takes place in the same way, starting from V-demethyl-podophyllotoxin, as per mol V-demethyl podophyllotoxin 1 - 1.6 mol carbobenzoxychloride is used.
De nye forbindelser med den alminnelige formel I besitter in vitro en hoy cytostatisk virkning på mastocytomceller og fibroblast-kulturer. Videre utmerker de seg ved en sterk virksomhet overfor eksperimentelle tumorer, særlig/fot museleukemi L-1210. De nye forbindelser med den alminnelige formel (I) kan anvendes terapeutisk for bekjempelse av patologiske prosesser som vedrorer celleformeringen, f.eks. maligne neoplasmer. The new compounds of the general formula I possess in vitro a high cytostatic effect on mastocytoma cells and fibroblast cultures. Furthermore, they are distinguished by their strong activity against experimental tumours, especially/foot mouse leukemia L-1210. The new compounds with the general formula (I) can be used therapeutically to combat pathological processes related to cell proliferation, e.g. malignant neoplasms.
For mer spesifikk påvisning av de foreliggende forbindelsers overlegenhet i forhold til de forbindelser som er omhandlet i DAS 1.020.639, anfores folgende: Overlegenhet med hensyn til hemmende virkning av de folgende forbindelser, henholdsvis: V-demetyl-epipodofyllotoksin-B-D-benzyliden-glukosid (1), V-demetyl-epipodofyllotoksin-B-D-tenyliden-glukosid (2), For more specific demonstration of the superiority of the present compounds in relation to the compounds referred to in DAS 1,020,639, the following is cited: Superiority with respect to the inhibitory effect of the following compounds, respectively: V-demethyl-epipodophyllotoxin-B-D-benzylidene-glucoside (1), V-demethyl-epipodophyllotoxin-B-D-tenylidene glucoside (2),
-dernetyl-epipodofyllotoksin-B-D-furfuryliden-glukosid (3)-dernetyl-epipodophyllotoxin-B-D-furfurylidene-glucoside (3)
i forhold til podofyllotoksin-benzyliden-B-D-glukosid (<>>+) in relation to podophyllotoxin-benzylidene-B-D-glucoside (<>>+)
(eksempel 1, DAS 1.020.639) kan enkelt demonstreres ved virkningen (Example 1, DAS 1,020,639) can be easily demonstrated by the action
av disse forbindelser på kulturer av rnastcelle-tumor P-815 i mus. Tilsettes forbindelsene (1), (2), (3), og ( h) til en slik celle-kultur i forskjellige konsentrasjoner i lopet av h0 timer, så oppnår man med de fire stoffer en $ 0% hemming av celleformeringen. Denne konsentrasjon eller dose betegnes som DE^Q. of these compounds on cultures of mouse stem cell tumor P-815. If the compounds (1), (2), (3) and (h) are added to such a cell culture in different concentrations over the course of h0 hours, the four substances achieve a $0% inhibition of cell proliferation. This concentration or dose is designated as DE^Q.
Det fremgår av den ovenstående tabell at forbindelsene (1), (2) og (3) in vitro har en vesentlig sterkere cytostatisk virkning enn forbindelsen ( h). Den nevnte in-vitro-virkning gir således med det i det folgende anforte in-vivo-forsok en antydning om at de i henhold til oppf innelæn fremstillbare forbindelser også kan ha en klinisk virkning. It appears from the above table that the compounds (1), (2) and (3) in vitro have a significantly stronger cytostatic effect than the compound (h). The aforementioned in-vitro effect thus gives, with the following in-vivo experiment, a hint that the compounds that can be produced according to the invention can also have a clinical effect.
Den overlegne virkning av forbindelsen (1) i forhold til forbindelsen C+) på formeringen av maligne celler in vivo ble provet eksperimentelt på transplanterbar musetumor, museleukemi L-1210. Det viste seg ved dette at det med forbindelsen ( h) ikke kunne oppnås noen nevneverdig terapeutisk virkning, men at derimot forbindelsen (1) i lav adekvat dosering viste en bemerkelsesverdig virkning (forlengelsen av overlevingstiden til 150$ eller mer). The superior effect of the compound (1) compared to the compound C+ on the proliferation of malignant cells in vivo was tested experimentally on a transplantable mouse tumor, mouse leukemia L-1210. This showed that no appreciable therapeutic effect could be achieved with the compound (h), but that, on the other hand, the compound (1) in a low adequate dosage showed a remarkable effect (the extension of the survival time to 150$ or more).
Injeksjonene av forbindelsene "(1) og ( h) ble igangsatt på datoen for tumorpodingen og fortsatt til dyrets ddd. Det ble per dose anvendt 6 mus. I de enkelte forsok ble overlevningstiden (OLT)J dvs. tiden for datoen for tumorpodingen til doden inntraff, målt i dager. The injections of the compounds "(1) and (h) were started on the date of tumor inoculation and continued until the animal's ddd. Six mice were used per dose. In the individual experiments, the survival time (OLT)J, i.e. the time from the date of tumor inoculation to death occurred, measured in days.
Doseringen av de nye forbindelser med den alminnelige formel (I) varierer mellom 1 og 50 mg pr. dogn. The dosage of the new compounds with the general formula (I) varies between 1 and 50 mg per day and night.
De nye forbindelser kan anvendés som legemidler i seg selv eller i tilsvarende legemiddelformer for- oral, enteral eller parenteral adminstrering. For fremstilling av egnede legemiddelformer forarbeides forbindelsene med organiske eller uorganiske, farmakologisk indifferente hjelpestoffer. 1 de etterfølgende eksempler er alle temperaturangivelser i grader Celsius.Smelte-henholdvis spaltingspunktene er bestemt på Kofler-blokk. The new compounds can be used as drugs in themselves or in corresponding drug forms for oral, enteral or parenteral administration. For the production of suitable pharmaceutical forms, the compounds are processed with organic or inorganic, pharmacologically indifferent excipients. 1 the following examples are all temperature indications in degrees Celsius. The melting and splitting points respectively are determined on the Kofler block.
Eksempel 1-7 illustrerer fremstilling av utgangsmaterialer. Examples 1-7 illustrate the production of starting materials.
Eksempel 1: \ t ' - demetyl- epipodofyllotoksinExample 1: \t'-demethyl-epipodophyllotoxin
2 g -demetyl-podofyllotoksin loses i 25 ml aceton og 15 ml vann og etter tilsetning av 5 ml konsentrert saltsyre oppvarmes i 2 timer under tilbakelop. Deretter nøytraliseres syren med Dissolve 2 g of demethyl podophyllotoxin in 25 ml of acetone and 15 ml of water and, after adding 5 ml of concentrated hydrochloric acid, heat for 2 hours under reflux. The acid is then neutralized with
fast bariumkarbonat, det filtreres og filtratet befris for aceton i vakuum ved<1>+0°C. Det utfélte material opptas i kloroform pluss 5% aceton, losningen torres over natriumsufat og inndampes i vakuum. Resten kromatograferes på silikagel med kloroform + 1% metanol, hvorved det forst erholdes små mengder forurensninger, deretter rent V-demetyl-epipodofyllotoksin og til slutt uomsatt utgangsmaterial. Krystallisering av de rene fraksjoner av V-demetyl-epipodofyllotoksin skjer fra kloroform og metanol. Smeltepunkt 228 - 230°C, Æ/jj0 = -69.8° (c = 0,630 i kloroform). solid barium carbonate, it is filtered and the filtrate is freed from acetone in vacuum at <1>+0°C. The precipitated material is taken up in chloroform plus 5% acetone, the solution is dried over sodium sulfate and evaporated in vacuo. The residue is chromatographed on silica gel with chloroform + 1% methanol, whereby first small amounts of impurities are obtained, then pure V-demethyl-epipodophyllotoxin and finally unreacted starting material. Crystallization of the pure fractions of V-demethyl-epipodophyllotoxin takes place from chloroform and methanol. Melting point 228 - 230°C, Æ/jj0 = -69.8° (c = 0.630 in chloroform).
Eksempel 2; h }- karbobenzoksy- H-'- demetyl- epipodofyllotoksinExample 2; h }- carbobenzoxy- H-'- demethyl- epipodophyllotoxin
60 g stovfint pulverisert h<*->demetyl-epipodofyllotoksin 60 g finely powdered h<*->demethyl-epipodophyllotoxin
suspenderes i 1000 ml vannfritt etylenklorid og avkjoles etter tilsetning av 19 ml abs. pyridin til -10°C. Under roring og utelukkelse av fuktighet tildryppes ved -10°C i lopet av 2,5 time en losning av 3*f g klormaursyre-benzylester i 100 ml etylenklorid og deretter hensettes det ytterligere i time for omsetning. Deretter vaskes reaksjonslosningen med vann, den organiske fase torres over natriumsulfat, inndampes i vakuum og resten torres i hoyvakuum ved 70-8o°C. Krystallisering av råproduktet fra aceton/eter og deretter 2 ganger fra metanol gå h<*->karbobenzoksy-k*-demetyl-epipodofyllotoksin med dobbelt smeltepunkt 117 - 119/202 suspended in 1000 ml of anhydrous ethylene chloride and cooled after adding 19 ml of abs. pyridine to -10°C. While stirring and exclusion of moisture, a solution of 3.5 g of chloroformic acid benzyl ester in 100 ml of ethylene chloride is added dropwise at -10°C over the course of 2.5 hours and then left to react for a further hour. The reaction solution is then washed with water, the organic phase is dried over sodium sulphate, evaporated in a vacuum and the residue is dried in a high vacuum at 70-8o°C. Crystallization of the crude product from acetone/ether and then 2 times from methanol go h<*->carbobenzoxy-k*-demethyl-epipodophyllotoxin with double melting point 117 - 119/202
- 205°C. Ved torring i hoyvakuum forst ved 95 - 110°C og deretter ved 130°C eller krystallisering fra aceton/eter erholdes den losningsmiddelfri form med smeltepunkt 201 - 20k°C, £% f^~ = -<*>+3j9° - 205°C. By drying in high vacuum first at 95 - 110°C and then at 130°C or crystallization from acetone/ether, the solvent-free form is obtained with melting point 201 - 20k°C, £% f^~ = -<*>+3j9°
(c = 0,535) i CHC13- (c = 0.535) in CHC13-
Eksempel 3: h '- karbobenzoksy-^'- demetyl- podofyllotoksinExample 3: h'-carbobenzoxy-^'-demethylpodophyllotoxin
15,Og h<1->demetyl-podofyllotoksin loses i hjO ml varm abs. etylenklorid- tetrahydrofuran-blanding (1:1), tilsettes 6,0 ml abs. pyridin og avkjoles til -10°C: Under roring og kjoling tildryppes nå i lopet av li time 8 ml klormaursyrebenzylester, lost i 55 ml etylenklorid, og deretter rores i 1 time ved -5 - -10°C. Deretter inndampes i vakuum ved<1>+0°C badtemperatur til et volum på 200 ml, det fortynnes med 250 ml etylenklorid og losningen vaskes en gang 15, And h<1->demethyl-podophyllotoxin is dissolved in hjO ml of warm abs. ethylene chloride-tetrahydrofuran mixture (1:1), add 6.0 ml abs. pyridine and cooled to -10°C: While stirring and cooling, 8 ml of chloroformate benzyl ester, dissolved in 55 ml of ethylene chloride, are now added dropwise over the course of 1 hour, and then stirred for 1 hour at -5 - -10°C. It is then evaporated in a vacuum at <1>+0°C bath temperature to a volume of 200 ml, it is diluted with 250 ml of ethylene chloride and the solution is washed once
med 100 ml 1 N saltsyre og deretter til noytral tilstand med vann. Etter torring over natriumsulfat inndampes i vakuum og resten kromatograferes på den 20-dobbelte mengde silikagel. Kloroform med Vfo metanol eluerer forst små mengder biprodukter, deretter rent *+' -karbobenzoksy-^f'-demetyl-podofyllotoksin. Etter krystallisering fra metanol smelter forbindelsen ved 113 - lllf°C. faj*<1>= -88,3°C (kloroform). with 100 ml of 1 N hydrochloric acid and then until neutral with water. After drying over sodium sulphate, it is evaporated in vacuo and the residue is chromatographed on the 20-fold quantity of silica gel. Chloroform with Vfo methanol first elutes small quantities of by-products, then pure *+' -carbobenzoxy-^f'-demethyl-podophyllotoxin. After crystallization from methanol, the compound melts at 113 - 111°C. faj*<1>= -88.3°C (chloroform).
Eksempel h: Tetra-O-acetyl-^'-karbobenzoksy-V-demetyl-epipodofyllotoksin- 3- D- glukosid Example h: Tetra-O-acetyl-^'-carbobenzoxy-V-demethyl-epipodophyllotoxin-3-D-glucoside
10,7 g ^! -karbobenzoksy-M-1 -demetyl-podofyllotoksin loses under oppvarming i 30 ml etylenklorid, losningen avkjoles til +15°C og tilsettes lH-,0 g 2,3 , k,6-tetra-0-acetyl-3-D-glukose. Etter 5 minutters roring avkjoles under utelukkelse av fuktighet til -15°C og i lopet av 5 minutter tildryppes 7 ml til -10°C forhånds-avkjolt bortrifluorid-etyleterat (h8% BF^). 10.7 g ^! -carbobenzoxy-M-1-demethyl-podophyllotoxin is dissolved while heating in 30 ml of ethylene chloride, the solution is cooled to +15°C and 1H-,0 g of 2,3,k,6-tetra-0-acetyl-3-D- glucose. After 5 minutes of stirring, it is cooled to -15°C while excluding moisture and, over the course of 5 minutes, 7 ml of pre-cooled boron trifluoride ethyl etherate (h8% BF^) is added dropwise to -10°C.
Deretter rores i 1 time ved -15°C, og så tildryppes en losningThe mixture is then stirred for 1 hour at -15°C, and then a solution is added drop by drop
av 7 ml abs. pyridin i 20 ml etylenklorid. Etter fortynning med 100 ml kloroform vaskes 5 ganger med hver gang 50 ml vann. Den organiske fase torres over natriumsulfat, det inndampes i vakuum og resten torres i vakuum ved 60°C. Det erholdte skum loses i 50 ml varm etanol, avkjoles til ca. 50°C, tilsettes 150 ml kaldt vann og det rores så lenge at det til å begynne med klumpede og seige bunnfall er forvandlet til et sandaktig pulver. Produktet avsuges, ettervaskes med h0 ml 25$ etanol og torres i vakuum ved 60°C. Deretter loses preparatet i 200 ml varm metan'61, filtreres klart, filtratet inndampes i vakuum og resten torres i hoyvakuum ved 80°C til konstant vekt. Det på denne måte erholdte tetra-0-acetyl-V -karbobenzoksy-Lt-' -demetyl-epipodofyllotoksin-Ø-D-glukosid er identisk med det etter eksempel 3 fremstilte preparat. of 7 ml abs. pyridine in 20 ml of ethylene chloride. After dilution with 100 ml of chloroform, wash 5 times with 50 ml of water each time. The organic phase is dried over sodium sulphate, it is evaporated in a vacuum and the residue is dried in a vacuum at 60°C. The resulting foam is dissolved in 50 ml of hot ethanol, cooled to approx. 50°C, 150 ml of cold water is added and it is stirred for so long that the initially lumpy and tough precipitate is transformed into a sandy powder. The product is suctioned off, washed with 0 ml of 25% ethanol and dried in a vacuum at 60°C. The preparation is then dissolved in 200 ml of hot methane'61, filtered clearly, the filtrate is evaporated in a vacuum and the residue is dried in a high vacuum at 80°C to constant weight. The tetra-O-acetyl-V-carbobenzoxy-Lt-'-demethyl-epipodophyllotoxin-Ø-D-glucoside obtained in this way is identical to the preparation prepared according to example 3.
Eksempel 5; Tetra-0-acetyl-lf' -demetyl-epipodofyllotoksin-B-D-glukosid Example 5; Tetra-O-acetyl-1f'-demethyl-epipodophyllotoxin-B-D-glucoside
For avspalting av karbobenzoksyresten fra tetra-O-acetyl-^1 - karbobenzoksy-^'-demetyl-epipodofyllotoksin-p-D-glukosid loses 13,g av denne forbindelse i 100 ml aceton etanol (1:2), tilsettes 0,5 ml iseddik og 2 g palladium-kull (med 10% Pd) og hydreres ved 20°C. Deretter frafiltreres katalysatoren, denne ettervaskes med varm aceton-metanol-blanding og filtratet inndampes i vakuum. Resten overhelles med 100 ml kokende etanol, får/henstå for krystallisering og krystallene torres i vakuum etter avsugning og vasking med metanol. Rent tetra-O-acetyl-V -karbobenzoks<y>-V -demetyl-epipodofyllotoksin-B-D-glukosid krystalliserer i fine nåler med smeltepunkt 225 - 227°C, ZV^<1>= -6^,^° (c = 1,02^) i kloroform. To cleave off the carbobenzoxy residue from tetra-O-acetyl-^1 - carbobenzoxy-^'-demethyl-epipodophyllotoxin-p-D-glucoside, dissolve 13.g of this compound in 100 ml of acetone ethanol (1:2), add 0.5 ml of glacial acetic acid and 2 g of palladium charcoal (with 10% Pd) and hydrated at 20°C. The catalyst is then filtered off, this is washed with a hot acetone-methanol mixture and the filtrate is evaporated in a vacuum. The residue is poured over with 100 ml of boiling ethanol, allowed to crystallize and the crystals are dried in vacuum after suction and washing with methanol. Pure tetra-O-acetyl-V -carbobenzox<y>-V -demethyl-epipodophyllotoxin-B-D-glucoside crystallizes in fine needles with melting point 225 - 227°C, ZV^<1>= -6^,^° (c = 1.02^) in chloroform.
Eksempel 6: - demetyl- epipodofyllotoksin- B- D- glukosidExample 6: - demethyl-epipodophyllotoxin-B-D-glucoside
25 g rent tetra-O-acetyl-V -karbobenzoksy-V-demetyl-epipodofyllotoksin-B-D-glukosid, 3?6 g vannfritt sinkacetat og l,>+5 g vannfritt natriumacetat oppvarmes i 150 ml metanol under tilbakelop og roring. Etter 2 og h timer avdestilleres hver gang 12, 5 ml metanol. Deretter tilsettes etter hver 2.time 12,5 ml metanol og avdestilleres pånytt. Etter i alt 18 timer er avspaltingen av acetylgruppene avsluttet og det foreligger en blanding av ca. 60% h1 -karbobenzoksy-V -demetyl-epipodofyllotoksin-B-D-glukosid og ca. k0% V-demetyl-epipodofyllotoksin-B-D-glukosid. Reaksjonen folges i tynnskikt-kromatogram på silikagelplater med vannmettet isopropylacetat/metanol (^il) som stromningsmiddel. Kromato-grammene fremkalles ved dusjing med en 0, 2% losning av Ce (IV) sulfat i 50$ svovelsyre og oppvarming til 110 - 130°C. 25 g of pure tetra-O-acetyl-V-carbobenzoxy-V-demethyl-epipodophyllotoxin-B-D-glucoside, 3.6 g of anhydrous zinc acetate and 1.5 g of anhydrous sodium acetate are heated in 150 ml of methanol under reflux and stirring. After 2 and h hours, 12.5 ml of methanol are distilled off each time. Then, after every 2 hours, 12.5 ml of methanol is added and distilled again. After a total of 18 hours, the cleavage of the acetyl groups is complete and there is a mixture of approx. 60% h1-carbobenzoxy-V-demethyl-epipodophyllotoxin-B-D-glucoside and approx. k0% V-demethyl-epipodophyllotoxin-B-D-glucoside. The reaction is followed in a thin-layer chromatogram on silica gel plates with water-saturated isopropyl acetate/methanol (µl) as eluant. The chromatograms are developed by showering with a 0.2% solution of Ce (IV) sulphate in 50% sulfuric acid and heating to 110 - 130°C.
For opparbeiding tilsettes 5 ml iseddik, det inndampes i vakuumFor processing, 5 ml of glacial acetic acid is added, it is evaporated in a vacuum
ved 50°C badtemperatur og det torres i 15 minutter i hoyvakuum ved 50°C Resten opptas i 250 ml kloroform/isopropanol ( h:l) og 25 ml vann, den vandige fase fraskilles og den organiske fase vaskes ytterligere med 25 ml vann. De to vaskevann ekstraheres med 50 ml kloroform/isopropanol og de forenede organiske faser inndampes i vakuum etter torring over natriumsulfat. Resten destilleres 3 ganger med hver gang 30 ml aceton i vakuum og torres deretter i 2 timer i hoyvakuum ved 75°C. at 50°C bath temperature and it is dried for 15 minutes in high vacuum at 50°C. The residue is taken up in 250 ml chloroform/isopropanol (h:1) and 25 ml water, the aqueous phase is separated and the organic phase is further washed with 25 ml water. The two washing waters are extracted with 50 ml of chloroform/isopropanol and the combined organic phases are evaporated in vacuo after drying over sodium sulphate. The residue is distilled 3 times with each time 30 ml of acetone in vacuum and then dried for 2 hours in high vacuum at 75°C.
Fra blandingen av h.' -karbobenzoksy-^-' -demetyl-epipodofyllotoksin-B-D-glukosid og<1>+'rdemetyl-epipodofyllotoksin-B-D-glukosid kan From the mixture of h.' -carbobenzoxy-^-'-demethyl-epipodophyllotoxin-B-D-glucoside and<1>+'rdemethyl-epipodophyllotoxin-B-D-glucoside can
man ved krystallisering fra metanol utvinne >+' -karbobenzoksy-V - by crystallization from methanol, >+' -carbobenzoxy-V -
demetyl-epipodofyllotoksin-B-D-glukosid i ikke helt ren form.. Kromatografering på den 100-dobbelte mengde silikagel gir demethyl-epipodophyllotoxin-B-D-glucoside in not completely pure form. Chromatography on the 100-fold amount of silica gel gives
etter eluering med vannmettet isopropylacetat/metanol (9:1)after elution with water-saturated isopropyl acetate/methanol (9:1)
rent !+' -karbobenzoksy-V -demetyl-epipodofyllotoksin-B-D-glukosid, som krystallisert fra aceton smelter ved 155-156°C. pure !+' -carbobenzoxy-V -demethyl-epipodophyllotoxin-B-D-glucoside, which crystallized from acetone melts at 155-156°C.
Æi/p1 = -92,0° (c = 1,00) i kloroform.Æi/p1 = -92.0° (c = 1.00) in chloroform.
For avspaltingen av karbobenzoksygruppen loses blandingen av For the cleavage of the carbobenzoxy group, the mixture is dissolved
>+' -karbobenzoksy-Ll-, -demetyl-epipodofyllotoksin-(3-D-glukosid og V-demetyl-epipodofyllotoksin-B-D-glukosid i 200 ml aceton, losningen tilsettes til en suspensjon av 3g palladium-kull (10$ Pd) i 50 ml vann og det hydreres til avsluttet avspalting av beskyttelsesgruppen (1,5 "time). Kontroll av reaksjonen ved tynnskiktskromatogram som ovenfor. Deretter filtreres katalysatoren fra, denne ettervaskes med 100 ml aceton-vann (M-:l) og filtratet inndampes i vakuum til et volum på ca.<1>+0-<1>+5 ml, hvorved lett V-dernetyl-epipodofyllotoksin-B-D-glukosid utkrystalliserer. For fullstendig krystallisering får blandingen stå ennå i 20 min. i isbad, de utfelte krystaller avsuges, vaskes med 25 ml vann og torres i hoyvakuum ved 70°C. Krystallisering fra metanol gir rent h'-demetyl-epipodofyllotoksin-B-D-glukosid med smeltepunkt 225-227°C, / U^ 1 = -88,6° (c = 1,05) i metanol. En annen modifikasjon viser smeltepunkt 262-26<*>4-°C. >+' -carbobenzoxy-Ll-, -demethyl-epipodophyllotoxin-(3-D-glucoside and V-demethyl-epipodophyllotoxin-B-D-glucoside in 200 ml of acetone, the solution is added to a suspension of 3g of palladium charcoal (10$ Pd) in 50 ml of water and it is hydrated until the removal of the protecting group is complete (1.5 hours). Control of the reaction by thin-layer chromatogram as above. The catalyst is then filtered off, this is washed with 100 ml of acetone-water (M-:1) and the filtrate is evaporated in vacuum to a volume of approx. crystals are filtered off, washed with 25 ml of water and dried in high vacuum at 70° C. Crystallization from methanol gives pure h'-demethyl-epipodophyllotoxin-B-D-glucoside with melting point 225-227° C, / U^ 1 = -88.6° (c = 1.05) in methanol Another modification shows mp 262-26<*>4-°C.
Eksempel 7: - dernetyl- epipodofyllotoksin- B- D- glukosidExample 7: - dernetyl-epipodophyllotoxin-B-D-glucoside
2,0 g,av det i eksempel 7 erholdte tetra-O-acetyl-4-' -demetyl-epipodofyllotoksin-B-D-glukosid og 1 g vannfritt zinkacetat oppvarmes i 30 ml absolutt metanol i 25 timer under tilbakelop. Deretter bringes det dannede hvite bunnfall i losning ved tilsetning av få ml iseddik og forsiktig oppvarming, losningsmidlet fjernes i vakuum ved h0°C og resten opptas i 50 ml kloroform/ butanol (*f:l). Den organiske fase vaskes to ganger'med hver gang 10 ml vann, det inndampes i vakuum etter torring over natriumsulfat og resten kromatograferes på silikagel. Vannmettet isopropylacetat/metanol (9:1) eluerer forst upolare andeler, deretter rent h'-demetyl-epipodofyllotoksin-B-D-glukosid. De enkelte fraksjoner undersokes i tynnskiktskromatogram på silikagel- 2.0 g of the tetra-O-acetyl-4-'-demethyl-epipodophyllotoxin-B-D-glucoside obtained in Example 7 and 1 g of anhydrous zinc acetate are heated in 30 ml of absolute methanol for 25 hours under reflux. The white precipitate formed is then dissolved by adding a few ml of glacial acetic acid and gently heating, the solvent is removed in vacuo at h0°C and the residue is taken up in 50 ml of chloroform/butanol (*f:l). The organic phase is washed twice with 10 ml of water each time, it is evaporated in vacuo after drying over sodium sulphate and the residue is chromatographed on silica gel. Water-saturated isopropyl acetate/methanol (9:1) first elutes non-polar portions, then pure h'-demethyl-epipodophyllotoxin-B-D-glucoside. The individual fractions are examined in thin-layer chromatograms on silica gel
plater med vannmettet isopropylacetat/metanol (8:1), som stromningsmiddel og glukosidfraksjonene forenes og krystalliseres to ganger fra metanol, ^f1 -demetyl-epipodofyllotoksin-8-D-glukosid smelter ved 222-230°C, en annen modifikasjon ved 262-26M-°C. frj2^=_88o (c=0?507) i metanol. Eksempel 8: i+ l- dernetyl- epipodofyllotoksin- B- D- benzyliden- glukosid plates with water-saturated isopropyl acetate/methanol (8:1), as eluent, and the glucoside fractions are combined and crystallized twice from methanol, ^f1 -demethyl-epipodophyllotoxin-8-D-glucoside melts at 222-230°C, another modification at 262- 26M-°C. frj2^=_88o (c=0?507) in methanol. Example 8: i+ l- dernetyl- epipodophyllotoxin- B- D- benzylidene- glucoside
1 g tdr.t ^'-demetyl-epipodofyllotoksin-B-D-glukosid loses i 20 ml 1 g tdr.t ^'-demethyl-epipodophyllotoxin-B-D-glucoside is dissolved in 20 ml
rent benzaldehyd og etter tilsetning av 0,5 g vannfritt sinkklorid rystes i rystemaskin under utelukkelse av fuktighet i 5-6 timer pure benzaldehyde and, after adding 0.5 g of anhydrous zinc chloride, shake in a shaking machine while excluding moisture for 5-6 hours
ved 20°C. Reaksjonens gang folges ved hjelp av tynnskiktkromatografering. For dette egner seg silikagelplater og kloroform med 6% metanol som stromningsmiddel. For å gjore substansene synlige dusjes platene med en 1% losning av Ce (IV)- ammonium-nitrat i 50$ svovelsyre og deretter oppvarmes ved 100 til 120°C. For opparbeidelse av kondensasjonsproduktet tilsettes den klare rodbrunt farvede reaksjonslosning kloroform og utrystes med vann. Den vandige fase ekstraheres to ganger med kloroform. Samtlige kloroformfaser forenes, vaskes toganger med vann, torres over natriumsulfat og losningsmidlet avdampes i vakuum. Den erholdte oljeaktige rest utrives med pentan for å fjerne stadig vedheftende benzaldehyd til det erholdes et pulveraktig produkt. For videre rensning opptas benzylidenderivatet i 10 ml aceton og acetonlosningen tildryppes under roring til en mengde på 100 ml pentan, hvorved det erholdes en lysegul til hvit felling.. Råproduktet kan også renses ved kromatografering på silikagel-kolonner. For dette filtreres en så konsentrert losning som mulig av 1 g av det rå benzylidenderivat i en blanding av kloroform pluss 2% metanol på en kolonne av 200 g silikagel og det elueres med den samme losningsmiddelblanding. De tynnskikt-kromatografisk-enhetlige fraksjoner forenes og omfelles fra aceton/pentan. h<1->demetyl-epipodofyllotoksin-B-D-benzyliden-glukosid erholdes som hvitt pulver med smeltepunkt l82-l85°C. Omkrystallisering fra abs. etanol ga krystaller med smeltepunkt2k5-2k6°C. De optiske dreiningsverider utgjor: /h7^ - -99° at 20°C. The course of the reaction is followed using thin-layer chromatography. For this, silica gel plates and chloroform with 6% methanol as a flow agent are suitable. To make the substances visible, the plates are showered with a 1% solution of Ce (IV) ammonium nitrate in 50% sulfuric acid and then heated at 100 to 120°C. To work up the condensation product, chloroform is added to the clear red-brown colored reaction solution and shaken with water. The aqueous phase is extracted twice with chloroform. All chloroform phases are combined, washed twice with water, dried over sodium sulphate and the solvent evaporated in vacuo. The oily residue obtained is triturated with pentane to remove the still adhering benzaldehyde until a powdery product is obtained. For further purification, the benzylidene derivative is taken up in 10 ml of acetone and the acetone solution is added dropwise with stirring to a quantity of 100 ml of pentane, whereby a pale yellow to white precipitate is obtained. The crude product can also be purified by chromatography on silica gel columns. For this, a solution as concentrated as possible of 1 g of the crude benzylidene derivative in a mixture of chloroform plus 2% methanol is filtered on a column of 200 g of silica gel and eluted with the same solvent mixture. The thin-layer chromatographically uniform fractions are combined and reprecipitated from acetone/pentane. h<1->demethyl-epipodophyllotoxin-B-D-benzylidene-glucoside is obtained as a white powder with a melting point of 182-185°C. Recrystallization from abs. ethanol gave crystals with melting point 2k5-2k6°C. The optical degrees of rotation are: /h7^ - -99°
-i metanol og -lO^-0 i kloroform.-in methanol and -lO^-0 in chloroform.
Eksempel 9: - dernetyl- epipodofyllotoksin- B- D- tenyliden- glukosidExample 9: - dernetyl-epipodophyllotoxin-B-D-thenylidene-glucoside
0,5 g tort V-demetyl-epipodofyllotoksin-B-D-glukosid tilsettes 10 ml rent tiofen-2-aldehyd og 0,25 g vannfritt sinkklorid og blandingen rystes under utelukkelse av fuktighet ved 20°C på rystemaskin, hvorved det dannes en etterhvert klar losning. 0.5 g of dry V-demethyl-epipodophyllotoxin-B-D-glucoside is added to 10 ml of pure thiophene-2-aldehyde and 0.25 g of anhydrous zinc chloride and the mixture is shaken while excluding moisture at 20°C on a shaking machine, whereby a eventually clear solution.
Forlopet av kondensasjonen folges som ovenfor beskrevet vedThe course of the condensation is followed as described above by
hjelp av tynnskiktkromatografering. Etter 3 tllh timers reaksjonsforlop fortynnes losningen med kloroform og utrystes med vann. Kloroformfasen ettervaskes ennå to ganger med litt vann og torres så over natriumsulfat og inndampes. Den erholdte rest loses for fjernelse av overskytende tiofen-2-aldehyd i litt aceton og omfelles ved tilsetning av pentan. Omfellingen fra aceton-pentan gjentas inntil kondensasjonsproduktet faller ut i fnokket form. For videre rensing kromatograferes råproduktet på silikagel. De tynnskikt-kromatografisk-enhetlige fraksjoner forenes og gir krystaller fra absolutt alkohol. Rent V-demetyl-epipodofyllotoksin-B-D-tenyliden-glukosid har et smeltepunkt på 2<1>+2-2<1>+6<0>C (siste rester ved 255°C) og har i kloroform-metanol (9:1) den optiske dreining £hJ- q -107 • using thin layer chromatography. After 3 tllh hours of reaction, the solution is diluted with chloroform and shaken out with water. The chloroform phase is washed twice more with a little water and then dried over sodium sulphate and evaporated. The residue obtained is dissolved in a little acetone to remove excess thiophene-2-aldehyde and reprecipitated by adding pentane. The reprecipitation from acetone-pentane is repeated until the condensation product precipitates out in a crumbly form. For further purification, the crude product is chromatographed on silica gel. The thin-layer chromatographically uniform fractions are combined and give crystals from absolute alcohol. Pure V-demethyl-epipodophyllotoxin-B-D-tenylidene-glucoside has a melting point of 2<1>+2-2<1>+6<0>C (last residues at 255°C) and has in chloroform-methanol (9: 1) the optical rotation £hJ- q -107 •
Eksempel 10: -demetyl-epipodofyllotoksin-B-D-furfurylideri-Example 10: -demethyl-epipodophyllotoxin-B-D-furfurylidene-
glukosidglucoside
0,5 g tort V-demetyl-epipodofyllotoksin-B-D-glukosid tilsettes 10 ml ren furfurql og etter tilsetning av 0,25 g vannfritt sinkklorid rystes på rystemaskin under utelukkelse av fuktighet i 0.5 g of dry V-demethyl-epipodophyllotoxin-B-D-glucoside is added to 10 ml of pure furfurql and after the addition of 0.25 g of anhydrous zinc chloride is shaken on a shaking machine while excluding moisture in
3 til h timer ved 20°C. Forlopet av kondensasjonsreaksjonen kontrolleres tynnskiktskromatografisk. Tynnskiktkromatograferingen kan utfores på silikagelplater med kloroform med 6% metanol som stromningsmiddel. For å gjore stoffene synlige dusjes med en 1% losning av Ce(IV)-ammoniumnitrat i 50$ svovelsyre og deretter oppvarmes ved 100-120°C. Etter avsluttet kondensering tilsettes den gronnfarvede reaksjonslosning kloroform og deretter utrystes med vann. Den vandige fase ekstraheres to ganger med kloroform. Samtlige klorof ormf aser forenes, va.skesénnå to ganger med litt 3 to h hours at 20°C. The course of the condensation reaction is checked by thin-layer chromatography. The thin-layer chromatography can be carried out on silica gel plates with chloroform with 6% methanol as eluent. To make the substances visible, they are showered with a 1% solution of Ce(IV)-ammonium nitrate in 50% sulfuric acid and then heated at 100-120°C. After completion of condensation, chloroform is added to the green-coloured reaction solution and then shaken with water. The aqueous phase is extracted twice with chloroform. All chloroform phases are combined, washing twice with a little
vann, torres over natriumsulfat og losningsmidlet inndampes iwater, dried over sodium sulphate and the solvent evaporated
vakuum ved 60°C Den oljeaktige rest (ca. 10 ml) dryppes for fjerning av vedheftende furfurol under roring ned i 150 ml pentan, hvorved det erholdes en seig felling. Etter dekantering av overstående pentan opptas fellingen i litt aceton og denne losning tildryppes en mengde av 150 ml pentan. Det utskilte, nå flokkete kondensasjonsprodukt kan renses ved kromatografering på silikagel. For kromatografering tilfores en kolonne med 100 g silikagel en vacuum at 60°C. The oily residue (approx. 10 ml) is dropped into 150 ml of pentane with stirring to remove adhering furfurol, whereby a tough precipitate is obtained. After decanting the overlying pentane, the precipitate is taken up in a little acetone and a quantity of 150 ml of pentane is added dropwise to this solution. The separated, now flocculated condensation product can be purified by chromatography on silica gel. For chromatography, a column with 100 g of silica gel is supplied
konsentrert losning av råproduktet i kloroform pluss 2% metanol og det elueres med den samme lbsningsmiddelblanding. De tynnskikt-kromatografisk-enhetlige fbrstefraks joner forenes og omfelles fra aceton-pentan. h*-demet<y>l-e<p>i<p>odof<y>llotoksin-B-D-furfuryliden-glukosid erholdes som hvitt pulver med smeltepunkt 188-191 C. concentrated solution of the crude product in chloroform plus 2% methanol and it is eluted with the same solvent mixture. The thin-layer chromatographically uniform first fractions are combined and reprecipitated from acetone-pentane. h*-demet<y>l-e<p>i<p>odof<y>llotoxin-B-D-furfurylidene glucoside is obtained as a white powder with a melting point of 188-191 C.
Fra abs. metanol erholdes krystaller med smeltepunkt 267-269°C. Den optiske dreieverdi i kloroform er / qjj^ = -102°. From abs. methanol, crystals with a melting point of 267-269°C are obtained. The optical rotation value in chloroform is / qjj^ = -102°.
Eksempel 11: V- dernety1- epipodofy11otoksin- B- D- benzyliden- glukosid Example 11: V-dernety1-epipodophy11otoxin-B-D-benzylidene-glucoside
1,0 g finpulverisert -demetyl-epipodofyllotoksin-B-D-glukosid loses i 20 mg rent benzaldehyd og det tilsettes 2 g tort "Dowex" 50 WX 2" pulver. Luften i kolben fortrenges med nitrogen og reaksjonsblandingen rores under utelukkelse av fuktighet ved hjelp av magnetrorer. Forlopet av reaksjonen folges lopende ved hjelp av tynnskiktkromatografering. 1.0 g of finely powdered -demethyl-epipodophyllotoxin-B-D-glucoside is dissolved in 20 mg of pure benzaldehyde and 2 g of dry "Dowex" 50 WX 2" powder is added. The air in the flask is displaced with nitrogen and the reaction mixture is stirred while excluding moisture by means of The course of the reaction is followed continuously by means of thin-layer chromatography.
/Øystein a) kloroform pluss 6% metanol,/Øystein a) chloroform plus 6% methanol,
b) kloroform metanol vann- (70 :'25: 517 • b) chloroform methanol water- (70 :'25: 517 •
Etter 1 time er reaksjonen avsluttet.After 1 hour, the reaction is complete.
For opparbeidelse fra filtreres katolysator fra den gulrode losning og det ettervaskes godt med kloroform. Losningsmidlet fjernes ved 50°C i vakuum. Det erholdes en olje som renses på 60 g silikagel "Merck"-, (kornstorrelse 0,05 til 0,2 mm). Etter fraskilling av benzaldehydet med kloroformekstraksjon elueres substansen med kloroform pluss 2% metanol.. Denne kromatografiske rensing gir amorft<>>+'-demetyl-epipodofyllbtoksin-B-D-benzyliden-glukosid som er fullstendig enhetlig i tynnskiktskromatogram.. For .karakterisering loses preparatet i 5 ml aceton og tildryppes til 60 ral pentan under roring. k- 1 -demetyl-epipodofyllotoksin-B-D-benzyliden-glukosid erholdes som fatgelost amorft pulver med smeltepunkt l82-l81+°C. Fra abs. etanol erholdes krystaller med smeltepunkt 21f5-21+60C. For processing from, the catalyst is filtered from the yellowish solution and washed thoroughly with chloroform. The solvent is removed at 50°C in a vacuum. An oil is obtained which is purified on 60 g of silica gel "Merck" (grain size 0.05 to 0.2 mm). After separation of the benzaldehyde with chloroform extraction, the substance is eluted with chloroform plus 2% methanol. This chromatographic purification gives amorphous<>>+'-demethyl-epipodophyllbtoxin-B-D-benzylidene-glucoside which is completely uniform in a thin-layer chromatogram.. For .characterization, the preparation is dissolved in 5 ml of acetone and added dropwise to 60 ral of pentane while stirring. k-1-Demethyl-epipodophyllotoxin-B-D-benzylidene-glucoside is obtained as a barrel-dissolved amorphous powder with a melting point of 182-181+°C. From abs. ethanol, crystals with melting point 21f5-21+60C are obtained.
fvJv°=-1Qlf0 (c = 0,766 i kloroform). fvJv°=-1Qlf0 (c = 0.766 in chloroform).
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO17089667A NO121669B (en) | 1965-12-14 | 1967-12-08 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1723265A CH469000A (en) | 1965-12-14 | 1965-12-14 | Process for the production of new glucosides |
CH1722965 | 1965-12-14 | ||
CH1723065A CH507934A (en) | 1965-12-14 | 1965-12-14 | Epipodophyllotoxinglucosides |
CH1470366 | 1966-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO120371B true NO120371B (en) | 1970-10-12 |
Family
ID=27429581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO165984A NO120371B (en) | 1965-12-14 | 1966-12-13 |
Country Status (15)
Country | Link |
---|---|
AT (2) | AT298681B (en) |
BE (1) | BE691066A (en) |
CH (2) | CH507934A (en) |
DK (2) | DK120849B (en) |
ES (1) | ES334424A1 (en) |
FI (2) | FI47357C (en) |
FR (1) | FR6310M (en) |
GB (1) | GB1163106A (en) |
IL (3) | IL34853A (en) |
NL (1) | NL6617379A (en) |
NO (1) | NO120371B (en) |
OA (1) | OA02648A (en) |
SE (2) | SE337595B (en) |
SU (1) | SU414788A3 (en) |
YU (1) | YU33197B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713246A (en) * | 1984-03-19 | 1987-12-15 | Bristol-Myers Company | Etoposide oral dosage form |
US4965348A (en) * | 1989-05-19 | 1990-10-23 | Bristol-Myers Company | Dimeric epipodophyllotoxin glucoside derivatives |
US5036055A (en) * | 1989-06-07 | 1991-07-30 | Bristol-Myers Company | Acylated derivatives of etoposide |
-
1965
- 1965-12-14 CH CH1723065A patent/CH507934A/en not_active IP Right Cessation
- 1965-12-14 CH CH1723265A patent/CH469000A/en unknown
-
1966
- 1966-11-28 GB GB53218/66A patent/GB1163106A/en not_active Expired
- 1966-12-06 OA OA52682A patent/OA02648A/en unknown
- 1966-12-09 NL NL6617379A patent/NL6617379A/xx unknown
- 1966-12-10 YU YU2331/66A patent/YU33197B/en unknown
- 1966-12-12 SU SU1118481A patent/SU414788A3/ru active
- 1966-12-12 FI FI663294A patent/FI47357C/en active
- 1966-12-12 BE BE691066D patent/BE691066A/xx not_active IP Right Cessation
- 1966-12-12 AT AT1053668A patent/AT298681B/en active
- 1966-12-12 AT AT1142266A patent/AT295048B/en not_active IP Right Cessation
- 1966-12-12 ES ES334424A patent/ES334424A1/en not_active Expired
- 1966-12-12 IL IL34853A patent/IL34853A/en unknown
- 1966-12-12 IL IL27042A patent/IL27042A/en unknown
- 1966-12-13 SE SE17094/66A patent/SE337595B/xx unknown
- 1966-12-13 DK DK646366AA patent/DK120849B/en not_active IP Right Cessation
- 1966-12-13 NO NO165984A patent/NO120371B/no unknown
- 1966-12-13 SE SE03842/70A patent/SE370072B/xx unknown
-
1967
- 1967-03-10 FR FR98340A patent/FR6310M/fr not_active Expired
-
1968
- 1968-03-15 DK DK112368AA patent/DK118826B/en not_active IP Right Cessation
-
1970
- 1970-07-06 IL IL34853A patent/IL34853A0/en unknown
-
1971
- 1971-06-24 FI FI711801A patent/FI47358C/en active
Also Published As
Publication number | Publication date |
---|---|
FI47358C (en) | 1973-11-12 |
CH469000A (en) | 1969-02-28 |
YU233166A (en) | 1975-12-31 |
BE691066A (en) | 1967-06-12 |
GB1163106A (en) | 1969-09-04 |
YU33197B (en) | 1976-06-30 |
IL27042A (en) | 1971-04-28 |
ES334424A1 (en) | 1968-03-01 |
IL34853A0 (en) | 1970-09-17 |
OA02648A (en) | 1970-12-15 |
FI47357B (en) | 1973-07-31 |
CH507934A (en) | 1971-05-31 |
DK120849B (en) | 1971-07-26 |
FR6310M (en) | 1968-09-16 |
SE337595B (en) | 1971-08-16 |
NL6617379A (en) | 1967-06-15 |
FI47357C (en) | 1973-11-12 |
SU414788A3 (en) | 1974-02-05 |
AT295048B (en) | 1971-12-27 |
AT298681B (en) | 1972-05-25 |
SE370072B (en) | 1974-09-30 |
DK118826B (en) | 1970-10-12 |
FI47358B (en) | 1973-07-31 |
IL34853A (en) | 1971-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3524844A (en) | Epipodophyllotoxin glucoside derivatives | |
NO136459B (en) | ||
US3408441A (en) | Epipodophyllotoxin-beta-d-glucosides and derivatives thereof | |
US5036055A (en) | Acylated derivatives of etoposide | |
US3318926A (en) | 7alpha-methyl-16alpha-hydroxy-estrones | |
US2824874A (en) | Reserpic acid and derivatives | |
US7767798B2 (en) | Loganin analogues and a process for the preparation thereof | |
NO120371B (en) | ||
HU205132B (en) | Process for producing fluorine-substituted epipodophyllotoxin glycosides and pharmaceutical compositions comprising same as active ingredient | |
CN102391352B (en) | Amino acid derivatives of rotundic acid and application of derivatives in preparation of antitumor medicines | |
NO165984B (en) | STRONGLY ABSORBING OBJECTS. | |
US3452008A (en) | Novel 7-thioacyl-17-spirolactone gonanes | |
US5034380A (en) | Alkoxymethylidene epipodophyllotoxin glucosides | |
US2728763A (en) | Preparation of benzimidazole glycosides | |
DE1643521A1 (en) | New glucosides and a process for their preparation | |
NO174928B (en) | Analogous Process for Preparing Therapeutically Active Enol ethers of 6-Chloro-4-hydroxy-2-methyl-N- (2-pyridyl) -2H-thieno (2,3-e) -1,2-thiazine-3-carboxylic acid amide-1 , 1-dioxide | |
CN117586214B (en) | Linderane-type sesquiterpene dimer and preparation method and use thereof | |
NO170896B (en) | CLOTHING ELEMENT AND PROCEDURE FOR MANUFACTURING SUCH ITEMS | |
CN113979851B (en) | 2' -halogenated chalcone derivative, preparation method, pharmaceutical composition and application thereof | |
CN113730419B (en) | 20S,24R-epoxy-dammarane-3β,12β,25-triol derivatives and pharmaceutical compositions thereof | |
WO1999009043A1 (en) | Novel triterpene glycoside compound, process for preparation thereof and anti-cancer composition containing the same | |
WO2005116042A1 (en) | Treatment and prevention of cancer with new ginsenoside derivatives | |
US3277123A (en) | 16beta-lower alkylthio-17beta-hydroxy-estren-3-one and production thereof | |
US3573318A (en) | Nicotinic esters of acetophenone derivatives | |
US3310580A (en) | Colchicinic derivatives and process of preparation |